The registration follows TT’s earlier announcement of its new manufacturing facility in Asia which allows the company to further broaden its capabilities in direct response to demand from life science customers.
“Our FDA designation will provide a significant advantage in supporting our current customers,” says TT evp, Michael Leahan.
Manufacturing facilities that are involved in the production and distribution of medical devices intended for use in the United States are required to register annually with the FDA.
This registration provides the FDA with the location of medical device establishments and the devices manufactured at those establishments.
Knowing where devices are made increases the nation’s ability to prepare for and respond to public health emergencies.